Ocular pressure regulation

ABSTRACT

Disclosed are devices and methods of treating an ocular disorder including forming a self-sealing incision in a cornea into an anterior chamber of an eye; introducing through the incision a fluid drainage tube having a distal end, a proximal end and a longitudinal, internal lumen extending through the fluid drainage tube, wherein at least the proximal end passes through the anterior chamber; and implanting the distal end of the fluid drainage tube in fluid communication with the suprachoroidal space such that the proximal end of the fluid drainage tube remains in fluid communication with the anterior chamber.

RELATED APPLICATIONS

This application is a continuation of co-pending U.S. application Ser.No. 11/615,642, filed Dec. 22, 2006, entitled “OCULAR PRESSUREREGULATION” by Minas Coroneo, which is a continuation of U.S.application Ser. No. 10/712,277, filed Nov. 14, 2003, entitled “OCULARPRESSURE REGULATION” by Minas Coroneo, now U.S. Pat. No. 7,291,125,issued Nov. 6, 2007.

This application also is related to U.S. application Ser. No. [ATTORNEYDOCKET NO. 37528-503C05US], filed on this day herewith, and U.S.application Ser. No. [ATTORNEY DOCKET NO. 37528-503C07US], filed on thisday herewith, and U.S. application Ser. No. 12/905,003, filed Oct. 14,2010, entitled “OCULAR PRESSURE REGULATION” by Minas Coroneo; and toU.S. application Ser. No. 10/579,330, filed Nov. 12, 2004, entitled“OCULAR PRESSURE REGULATION” by Minas Coroneo; and to U.S. applicationSer. No. 11/615,615, Dec. 22, 2006, entitled “OCULAR PRESSUREREGULATION” by Minas Coroneo; and to U.S. application Ser. No.12/107,676, filed on Apr. 22, 2008, entitled “OCULAR PRESSUREREGULATION” by Minas Coroneo, now U.S. Pat. No. 7,815,592, issued Oct.19, 2010.

Where permitted, the subject matter of each of the above notedapplications is incorporated by reference in its entirety by referencethereto.

FIELD OF THE INVENTION

This invention is directed to therapeutic methods and devices for thetreatment of glaucoma. In particular, this invention is concerned withthe use of a shunt or drain for the treatment of glaucoma. In anotheraspect this invention is concerned with ocular pressure spike shunts anduse of the same in ocular surgery.

BACKGROUND OF THE INVENTION

The glaucomas are a common group of blinding conditions usuallyassociated with elevated intraocular pressure. This elevated pressure inthe eye may be regarded as a disorder of the drainage system of the eyewhich gives rise to the glaucomas.

Aqueous humor of the eye (“aqueous”) is a flowing liquid fluid (composedof sodium, chloride, bicarb, amino acids, glucose, ascorbic acid, andwater) that is actively secreted by the ciliary body and flows out pastthe iris into the anterior chamber (are between the lens/iris and thecornea). The aqueous drains out through angle formed by the iris and thesclera into a meshwork call the trabeculum, and from there into thecanal of Schlemm and then into the episcleral veins. Uveosclera drainagealso occurs. Normal intraocular pressure (TOP) of aqueous in anteriorchamber is between 10 and 20 mm Hg. Prolonged IOPs of greater than 21 mmHg are associated with damage to optic nerve fibers.

In some cases of glaucoma the cause can be found: the trabecularmeshwork becomes blocked by pigment or membrane. In other cases,blockage is due to a closure of the angle between the iris and thecornea. This angle type of glaucoma is referred to as “angle-closureglaucoma”. In the majority of glaucoma cases, however, called “openangle glaucoma”, the cause is unknown.

Elevated intraocular pressure results in the death of retinal ganglioncells (which convey retinal information to the brain) resulting in acharacteristic pattern of loss of the field of vision, progressing totunnel vision and blindness if left untreated.

Treatment of glaucoma consists predominantly of methods to lower theintraocular pressure (pharmacological, trabecular meshwork laser andsurgery to drain fluid from the eye). More recently protection of theretinal ganglion cells by neuroprotective agents has been attempted.

Although pharmacological treatments of glaucoma have improved, they haveimportant implications for the patient's quality of life, havecompliance issues which are important in the elderly (in whom glaucomais prevalent), expose the patient of glaucoma to side effects, and overa lifetime are costly.

Surgery for glaucoma treatment is usually a trabeculectomy in which afistula is created to drain fluid from the anterior chamber to thesubconjunctival space near the limbus, creating a bulge in theconjunctiva known as a bleb. Frequently scarring occurs and attempts tocounter this with antimetabolites such as Mitomycin C have met with somesuccess. In recalcitrant cases, glaucoma implants, drainage, shunt orvalve devices have been developed e.g. Molteno (U.S. Pat. No.4,457,757), Krupin (U.S. Pat. No. 5,454,746) and Baerveldt (U.S. Pat.No. 5,178,604). These suffer from similar problems of scarring (ClassenL, Kivela T, Tarkkanen “A Histopathologic and immunohistochemicalanalysis of the filtration bleb after unsuccessful glaucoma setonimplantation” Am J Ophthalmol, 1996; 122:205-12) around the externalopening of the tube devices in the subconjunctival space—the developmentof a large number of these devices is testament to the fact that manyfail in the longer term. In these devices a drainage tube is located inthe anterior chamber and is in fluid communication with the sclera or asurgically created subconjunctival space.

Whereas cataract surgery has been revolutionized in the last twodecades, improvements in glaucoma surgery have been slower. Antifibroticagents have improved the success rate of conventional filtration surgery(trabeculectomy), but with increased bleb leaks, blebitis,endophthalmitis and hypotensive maculopathy. Glaucoma shunts have hadlimited success in eyes that have “failed” multiple standard procedures.However complications with malpositioned tubes, erosion and strabismuspersist. A considerable issue is the lack of reproducibility andpredictability in achieving the desired target intraocular pressure(IOP). Final IOP is largely determined by healing which can beunpredictable—in view of vast biological variations, it is impossible topredict which eyes will rapidly scar causing failure and which will failto heal resulting in prolonged post-operative hypotony. Scarring remainsa significant problem in all these external drainage proposals, whereaqueous drains into the conjunctiva, or surgical chambers in the sclera.

The introduction of a new class of antiglaucoma drugs, the prostaglandinanalogues, has resulted in acknowledgment of the importance of theuveoscleral pathway in drainage of fluid form the eye (Hylton C, Robin AL “Update on prostaglandin analogs” Curr Opin Ophthalmol, 2003;14:65-9). Uveoscleral flow where aqueous humor flows through theinterstitium of the ciliary muscle into the suprachoroidal space (apotential space between the choroids and sclera) and out through thesclera into the connective tissue of the orbit may account for 54% ofoutflow young healthy humans (Toris C B, Yablonski M E, Wang Y L, CamrasC B “Aqueous humor dynamics in the aging human eye” Am J Ophthalmol,1999; 127:407-12).

Cyclodialysis, the separation of the ciliary body from the scleral spurand underlying sclera, creates free communication between the anteriorchamber and the suprachoroidal space and enhances uveoscleral flow. Ithas long been known that cyclodialysis can cause a profound reduction ofintraocular pressure—initially (Fuchs E. “Detachment of the choroidinadvertently during cataract surgery” [German] von Graefes ArchOphthalmol, 1900; 51:199-224) cyclodialysis was recognized as acomplication of cataract surgery. Deliberate creation of a cyclodialysiscleft for treating elevated intraocular pressure in uncontrolledglaucoma was first described as a surgical procedure in 1905 (Heine I.“Cyclodialysis, a new glaucoma operation” [German]) Dtsch MedWochenschr, 1905; 31:824-826). Since such clefts can heal and closespontaneously a number of devices have been used to keep them open,including platinum wire, horse hair, magnesium strips, tantalum foil,Supramid®, gelatin film, Teflon®, silicone and polymethylmethacrylate(Rosenberg L F, Krupin T. “Implants in glaucoma surgery” Chapter 88, TheGlaucomas, Ritch R, Shields B M, Krupin T Eds. 2^(nd) Edition Mosby StLouis 1986) and Hema (Mehta K R. “The suprachoroidal Hema wedge inglaucoma surgery” American Academy of Ophthalmology meeting 1977, pp144). However the success rate of such approaches has been low (as lowas 15%, Rosenburg & Krupin ibid and Gross R L, Feldman R M, Spaeth G L,et al “Surgical therapy of chronic glaucoma in aphakia and pseudophakia”Ophthalmology, 1988; 95:1195-201). Failure was due to uncontrolled lowpressure (hypotony) with consequential macular edema, bleeding (hyphema)and inadequate pressure control.

The device and method of a first aspect of this invention takesadvantage of the methods used in cataract surgery to develop a minimallyinvasive glaucoma procedure—thus small, self sealing incisions andmaterials that are biocompatible and foldable so that they fit throughsmall openings will reduce surgical trauma and time. The controlleddraining of aqueous into the suprachoroidal space according to thisinvention provides some predictability of outcome and overcomes scarringproblems that have plagued glaucoma implants in the past.

The most frequent complication following modern cataract surgery withphacoemulsification, requiring specific treatment is elevatedintraocular pressure (Cohen V M, Demetria H, Jordan K, Lamb R J, VivianA J.: First day post-operative review following uncomplicatedphacoemulsification” Eye, 1998; 12 (Pt 4):634-6, and Dinakaran S, DesaiS P, Raj P S. “Is the first post-operative day review necessaryfollowing uncomplicated phacoemulsification surgery?” Eye, 2000 June; 14(Pt 3A):364-6). The increase may be marked and typically peaks at 5 to 7hours before returning to near normal levels in 1 to 3 days (HildebrandG D, Wickremasinghe S S, Tranos P G, Harris M L, Little B C. “Efficacyof anterior chamber decompression in controlling early intraocularpressure spikes after uneventful phacoemulsification” J Cataract RefractSurg., 2003; 29:1087-92). Such pressure spikes can cause pain and mayincrease the risk of sight-threatening complications such as retinalvascular occlusion, increases loss of visual field in advanced glaucomaand ischemic optic neuropathy—effects in otherwise healthy eyes areunknown (Hildebrand G D et al, ibid).

A number of prophylactic treatments are used with limited success—theseinclude intracameral carbachol or acetylcholine, topical timolol,dorzolamide, aproclonidine, latanoprost and systemic acetazolamide (seeHildebrand G D et al, ibid). This also exposes the patient to the riskof drug side effects, increased cost and it has been postulated thatreducing the flow of aqueous humor post surgery prolongs the residencetime of bacteria that frequently (46.3% of cases) contaminate theanterior chamber during surgery (Srinivasan R, Tiroumal S, Kanungo R,Natarajan M K. “Microbial contamination of the anterior chamber duringphacoemulsification”

J Cataract Refract Surg, 2002; 28:2173-6.). This may increase the riskof endophthalmitis one of the most devastating sequelae of intraocularsurgery, since the bacteria are not being “flushed out” of the eye bythe normal production of aqueous humour, the secretion of which has beensuppressed by the drugs. Another technique is to decompress the anteriorchamber by applying pressure to the posterior lip of the paracentesiswound at the appropriate time. This requires surveillance and couldincrease the risk of infection. Another aspect of this inventionhereinafter described overcomes these problems.

SUMMARY OF THE INVENTION

According to the present invention there is provided a flexible oculardevice for implantation into the eye formed of a biocompatibleelastomeric material, foldable to a diameter of 1.5 mm or less,comprising a fluid drainage tube having at one end a foldable plateadapted to locate the device on the inner surface of the sclera in asuprachoroidal space formed by cyclodialysis, said drainage tube openingonto the disc at one end and opening to the anterior chamber whenimplanted into the eye at its other end, so as to provide aqueouspressure regulation.

Preferably the fluid drainage tube has a diameter selected to providepredetermined resistance to aqueous humor flow, for example a pressureof 10 mm Hg or less. Alternatively said tube contains a valve so as toregulate pressure of the aqueous chamber at a predetermined level, forexample, at no less than 10 mm Hg.

In accordance with another embodiment of this invention there isprovided a method for treating glaucoma which comprises:

-   -   providing a flexible ocular device formed of a biocompatible        elastomeric material foldable to a diameter of 1.5 mm or less,        comprising a fluid drainage tube having at one end a foldable        plate adapted to locate the device on the inner surface of the        sclera and at its other end being open so as to allow fluid        communication through said tube;    -   forming a small self-sealing incision at the juncture of the        cornea and sclera of the eye opening into the anterior chamber;    -   filling the anterior chamber with a viscoelastic substance;    -   introducing the foldable ocular device into a suprachoroidal        space formed by cyclodialysis via a hollow cannula, wherein said        plate locates the device on the inner surface of the sclera in        the suprachoroidal space, and said drainage tube is located in        the anterior chamber of the eye so as to provide aqueous humor        pressure regulation; and    -   thereafter removing said cannula and viscoelastic material from        the eye.

In another aspect there is provided an ocular pressure spike shunt forinsertion into an ocular paracentesis incision port following ocularsurgery, comprising a flexible fluid transfer tube formed ofbiocompatible material, preferably biocompatible elastomeric material,so as to allow paracentesis incision closure around said tube, having aninner end and an outer end, a tubular lumen disposed between said innerend and said outer end to allow fluid communication through said tube,said lumen containing a valve for controlling pressure in the eyefollowing ocular surgery, which valve opens permitting fluid flowthrough said tube when a predetermined pressure is exceeded, said shuntbeing configured such that on insertion into a paracentesis port saidouter end is substantially flush with the surface of the cornea, andsaid inner end opens into the anterior chamber of the eye.

In another aspect there is provided a method for preventing ocularpressure spikes following ocular surgery wherein a paracentesis incisionport is formed in the eye during said surgery, comprising introducing anocular pressure spike shunt into said paracentesis port at theconclusion of ocular surgery, said shunt comprising a flexible fluidtransfer tube formed of biocompatible material, preferably biocompatibleelastomeric material, so as to allow paracentesis incision closurearound said tube, having an inner end and an outer end, a tubular lumendisposed between said inner end and said outer end to allow fluidcommunication through said tube, said lumen containing a valve forcontrolling pressure in the eye following ocular surgery, which valveopens permitting fluid flow through said tube when a predeterminedpressure is exceeded, said shunt being configured such that on insertioninto a paracentesis port said outer end is substantially flush with thesurface of the cornea, and said inner end protrudes into the anteriorchamber of the eye.

DESCRIPTION OF THE FIGURES

FIG. 1 shows a diagrammatic representation of a side sectional view ofsuprachoroidal shunt insertion using an injector.

FIG. 2 shows a diagrammatic representation of a side sectional view ofan eye showing the unfolded plate portion of the device and a cannulaintroducing said device across the anterior chamber at 180° to the siteof insertion.

FIG. 3 shows a diagrammatic representation of an eye containing apressure spike shunt inserted into a paracentesis port.

FIG. 4 shows a perspective view of another embodiment of an oculardevice described herein.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

The ocular device according to the present invention is implanted in apatient's eye using minimally invasive surgery techniques, adopted frommodern cataract surgery.

The ocular device is formed from a biocompatible elastomeric material.Preferably, the device is made of soft surgical grade polymericmaterial, such as silicon or acrylic material such that the device isfoldable and may be rolled up for insertion via a cannula. FIG. 1 showsa proximal end of a cannula forming a cyclodialysis. The folded devicemay be introduced via such a cannula. The elastomeric material isselected to be sufficiently soft that it does not erode delicateunderlying choroid material when inserted into the eye. Such materialand ocular lenses formed therefrom are well known and used in cataractsurgery.

Sutures are not required to hold the device in place once surgicallyintroduced into the eye, as the foldable plate is adapted to locate thedevice on the inner surface of the sclera in a suprachoroidal spaceformed by cyclodialysis (FIG. 2). Preferably, the plate is of adisc-like shape which matches the curvature of the eye once unfolded.FIG. 2 depicts an unfolded disc (connected tube not shown) after cannulaintroduction across the anterior chamber (transcameral). Alternatively,any plate-like configuration which locates the device on the innersurface of the sclera in the suprachoroidal space may be used, such asfor example a rectangular foldable plate. Preferably the plate diameteris from 0.05 to 6 mm, and preferably the place thickness is from 12.5 μmto 250 μm. The fluid drainage tube of the ocular device is preferablyintegral with the plate, and is attached at one end to the plate,preferably at the periphery of the plate. Alternatively, the tube may bemicrowelded or otherwise fixed to the plate. Fabrication techniques wellknown in production of intraocular foldable lenses are preferably usedin this invention. The tube has a hollow lumen, and is preferably of alength from about 1 mm to 4 mm. Preferred diameters of the tubingcomprise an outer diameter of 400-1000 μm, and preferably the innerdiameter is from 50 to 500 μm.

The diameter of the tube may be selected so as to provide a resistanceto aqueous humor flow of predetermined pressure, preferably being apressure less than 10 mm Hg. This enables the pressure of the aqueous tobe regulated in a controlled manner, providing relief from excess ocularpressure associated with glaucoma, with avoidance of hypotony(uncontrolled low pressure). Alternatively, the tube may contain avalve, for example disposed at the end of the tube opening onto the discso as to regulate ocular pressure at a predetermined level. Preferably,the valve prevents aqueous flow through the tube at a pressure of lessthan 10 mm Hg. Examples of valves which may be used include a slitvalve. The drainage stops altogether if the pressure drops to apredetermined threshold level controlled by the valve.

The flexible foldable nature of the device according to the presentinvention enables well established techniques used in cataract surgeryto be employed in the treatment of glaucoma. The device according to thepresent invention may be folded into a cannula and introduced forlocation into the eye.

Intraocular surgery techniques allow a paracentesis (opening onto theanterior chamber from without at the juncture of the cornea andsclera—the limbus) to be performed and the anterior chamber filled withviscoelastic substance. A cyclodialysis instrument is introduced via theparacentesis, with the paracentesis preferably being carried out 180°from the insertion site. A cyclodialysis is carried out, for example byadvancing an instrument tip into the angle between the ciliary body andsclera so as to create a cyclodialysis. This is preferably carried outwith direct visualisation via gonioscopy lens viewed through anoperating microscope. A surgical gonioscopy lens is preferably placed onthe cornea while the cyclodialysis is carried out.

The rolled up ocular device is introduced through a cannula, for exampleusing an introducer such as used in cataract surgery or other ocularsurgery, from which the device can be detached by pressing a plungerinto the introducer when the device has been inserted into thesuprachoroidal space created by the cyclodialysis. The tubing of thedevice is positioned into the interior chamber, and the plate unfolds inthe suprachoroidal space to locate the device in the eye. Because of itssize, the device cannot fall through the opening through which it wasintroduced into the suprachoroidal space by the cyclodialysis. The platetherefore keeps the tube in the appropriate position in the anteriorchamber allowing controlled aqueous drainage and providing an effectivetreatment for elevated ocular pressure.

The pressure spike shunt is designed to fit snugly in a paracentesisport that is routinely made during cataract or other ocular surgery. Thetubing will not distort the port and there will be no leakage around theport. The outer end of the tube will sit flush on the surface of thecornea—the inner aspect of the tube will preferably just protrude intothe anterior chamber—tube length will generally be 1-2 mm and tubediameter is preferably from 0.4-1.2 mm. The tube will contain the samevalvular device as contained in the ocular device described above andwill open when the intraocular pressure exceeds a predetermined level,preferably 10 mm Hg. At normal ocular pressure the valve will be closed,closing said tube to any fluid communication. FIG. 3 shows a shuntlocated in a paracentesis port. In most cases the shunt will be removedand discarded at the first post-operative dressing.

The shunt may be inserted into a paracentesis port, or one or moreports, using, for example, a punctum plug inserting instrument such asdescribed in U.S. Pat. No. No. 5,741,292.

This invention will now be described with reference to the followingexamples.

EXAMPLE 1

Fresh whole porcine eyes were taken and mounted in a temperaturecontrolled (37°) perfusion chamber. The eyes were perfused with BalancedSalt Solution via a 30 gauge needle inserted via a paracentesis into theanterior chamber. A peristaltic pump was used at a flow rate of 2μl/min. Intraocular pressure was continuously monitored via a secondparacentesis.

Typically intraocular pressures stabilized at 10-15 mm Hg and fell withtime (the “washout effect”, as glycosan aminoglycans are washed out ofthe trabecular meshwork with time). Creation of a cyclodialysis(initially with a small spatula, then viscoelastic injection to enlargethe area of detachment of the ciliary body from the sclera) with orwithout insertion of the device in the cyclodialysis cleft (siliconetubing, length 3 mm, external diameter—1 mm, plate diameter 3 mm)resulted in lower intraocular pressures (below 10 mm Hg) on reperfusionat the same perfusion rate as control eyes.

EXAMPLE 2

Adequate anesthesia is provided to the eye of a glaucoma patientprepared for intraocular surgery. A paracentesis (opening into anteriorchamber from without at the junction of the cornea and sclera—thelimbus) is performed and the anterior chamber is filled with aviscoelastic substance. A surgical gonioscopy lens is placed on thecornea (or anterior segment endoscope is used) and a cyclodialysisinstrument is introduced via the paracentesis—the paracentesis iscarried out 180° away from the planned implant insertion site. Thecyclodialysis instrument tip is advanced into the angle and pushed intothe space between the ciliary body and sclera creating acyclodialysis—this is carried out with direct visualization via thegonioscopy lens viewed through an operating microscope. In order tominimize bleeding, the area in the angle (anterior ciliary body face andoverlying trabecular meshwork) can be lasered either preoperatively orat the time of surgery to ablate surface blood vessels).

Through an opening at the tip of the cyclodialysis instrumentviscoelastic is inserted to further create a space in the suprachoroidalspace. The implant is then introduced—the device is rolled up in thesame manner as an ultrathin intraocular lens. The ocular device isattached to an introducer from which it is detached by pushing a plungerin the introducer when the implant is inserted into the suprachoroidalspace created by the cyclodialysis instrument and viscoelastic. Thetubing is then positioned into the anterior chamber and may be cut tosize. The plate unfolds in the suprachoroidal space and because of itssize cannot fall through the opening through which it was introducedinto the suprachoroidal space. The plate therefore keeps the tube in anappropriate position. The valve is then flushed (with a cannula insertedvia the paracentesis) via the tube opening in the anterior chamber.Viscoelastic is then removed from the anterior chamber and antibiotics,steroids and a dressing applied to the eye.

EXAMPLE 3

Fresh whole porcine eyes were taken and mounted in atemperature-controlled (37°) perfusion chamber as in Example 1. The eyeswere perfused with Balanced Salt Solution via a 30 gauge needle insertedvia a paracentesis into the anterior chamber. A peristaltic pump wasused at a flow rate of 2 μl/min. Intraocular pressure was continuouslymonitored via a second paracentesis.

Typically intraocular pressures stabilized at 10-15 mm Hg and fell withtime (the “washout effect, as glycoaminoglycans are washed out of thetrabecular meshwork with time). Silicone tubing (length 3 mm, externaldiameter 1 mm) was introduced into one paracentesis port. One end of theport (outer end) was flush with the cornea and the inner end of the portextended slightly into the anterior chamber. Intraocular pressure didnot exceed 10 mm Hg.

1. A method of treating disease in an eye, comprising: introducing anophthalmic implant into the anterior chamber of the eye, wherein theophthalmic implant comprises an internal lumen through which aqueoushumor can flow and wherein the ophthalmic implant is introduced into theanterior chamber in its entirety; forming a passageway between theanterior chamber of the eye and the suprachoroidal space of the eye;positioning the ophthalmic implant in the passageway between theanterior chamber and the suprachoroidal space such that the internallumen of the ophthalmic implant provides fluid communication between theanterior chamber and the suprachoroidal space; and delivering asubstance and the ophthalmic implant into the eye.
 2. A method as inclaim 1, further comprising causing at least a portion of the ophthalmicimplant to expand while the ophthalmic implant is located in the eye,wherein the ophthalmic implant expands after the ophthalmic implant ispositioned in communication with the suprachoroidal space.
 3. A methodas in claim 1, further comprising causing at least a portion of theophthalmic implant to expand as the ophthalmic implant is introducedinto the eye.
 4. A method as in claim 1, wherein the internal lumen ofthe ophthalmic implant forms a first opening in a first end of theophthalmic implant and a second opening in a second end of theophthalmic implant and further comprising causing aqueous humor to flowfrom the anterior chamber into the suprachoroidal space through theinternal lumen.
 5. A method as in claim 1, wherein forming a passagewaybetween the anterior chamber of the eye and the suprachoroidal spacecomprises performing a cyclodialysis.
 6. A method as in claim 1,comprising forming a passageway between the anterior chamber of the eyeand the suprachoroidal space and positioning the ophthalmic implant inthe passageway after the passageway is formed.
 7. A method as in claim1, wherein introducing the ophthalmic implant into the anterior chamberof the eye in its entirety comprises passing a distal end and a proximalend of the ophthalmic implant through the cornea.
 8. A method as inclaim 1, further comprising performing a paracentesis with respect tothe cornea and the anterior chamber of the eye.
 9. A method as in claim8, wherein the paracentesis is performed in the limbus.
 10. A method asin claim 1, further comprising causing at least a portion of theophthalmic implant to expand while the ophthalmic implant is located inthe eye, wherein causing at least a portion of the ophthalmic implant toexpand comprises causing the ophthalmic implant to unfold.
 11. A methodas in claim 1, wherein the ophthalmic implant expands to a shape thatmatches the curvature of the eye.
 12. A method as in claim 11, whereinthe ophthalmic implant expands to a shape that matches the curvature ofthe eye in the suprachoroidal space.
 13. A method as in claim 1, whereinthe ophthalmic implant comprises a fluid drainage tube.
 14. A method asin claim 1, wherein positioning the ophthalmic implant comprisesinserting a distal end of the ophthalmic implant in the suprachoroidalspace.
 15. A method as in claim 7, wherein passing the distal end andthe proximal end of the ophthalmic implant through the cornea comprisessequentially passing the distal end and then the proximal end into theanterior chamber as the implant is being introduced.
 16. A method as inclaim 15, wherein the distal end and the proximal end of the ophthalmicimplant are sequentially passed such that the distal end and proximalend are concurrently located within the anterior chamber.
 17. The methodof claim 1, wherein forming a passageway between the anterior chamberand the suprachoroidal space comprises separating at least a portion ofthe ciliary body from at least a portion of the sclera.
 18. The methodof claim 17, wherein separating at least a portion of the ciliary bodyfrom at least a portion of the sclera comprises detaching the portion ofthe ciliary body from the portion of the sclera.
 19. The method of claim1, wherein the implant is used to form the passageway.
 20. The method ofclaim 1, wherein the substance comprises a viscoelastic substance. 21.The method of claim 20, wherein the substance is delivered into the eyeand then the ophthalmic implant is delivered into the eye.